[1] |
Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma[J]. Cancer,1956,9:822-830.
|
[2] |
Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman′s disease in HIV infection: a clinical and pathological study of 20 patients[J]. AIDS,1996,10:61-67.
|
[3] |
Saeed-Abdul-Rahman I, Al-Amri AM. Castleman disease[J]. Korean J Hematol,2012,47:163-177.
|
[4] |
Kurokawa T, Suzuki S, Kawaguchi K, et al. Castleman disease presenting with ophthalmic signs and symptoms[J]. Am J Ophthalmol,1999,128:114-116.
|
[5] |
Ibrahim K, Maghfoor I, Elghazaly A, et al. Successful treatment of steroid-refractory autoimmune thrombocytopenia associatedwith Castleman disease with anti-CD-20 antibody (rituximab) [J]. Hematol Oncol Stem Cell Ther,2011,4:100-102.
|
[6] |
Hoffmann C, Schmid H, Muller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric[J]. Castleman disease. Blood,2011,118:3499-3503.
|
[7] |
Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric. Castleman disease[J]. Blood,2010,116:3627-3634.
|
[8] |
Galeotti C, Boucheron A, Guillaume S, et al. Sustained remission of multicentric Castleman disease in children treated withtocilizumab, an anti-interleukin-6 receptor antibody[J]. Mol Cancer Ther,2012,11:1623-1626.
|